Repligen Reports Preliminary Financial Results for the Quarter and Nine-Month Fiscal Period Ended December 31, 2011

WALTHAM, Mass.--(BUSINESS WIRE)--Repligen Corporation (NASDAQ:RGEN) today reported preliminary financial results for the quarter and nine-month fiscal period ended December 31, 2011. These results reflect significant accomplishments of the Company during the period, highlighted by the completion of our acquisition of Novozymes Biopharma Sweden AB on December 20, 2011 and the successful filing of the Company’s first new drug application (NDA) for SecreFlo™ on December 21, 2011. These preliminary

Feed Date: 
February 21, 2012